Advanced Biomed

Recent actions include: a 1‑for‑20 reverse split to cure listing deficiency; sale of HK/PRC subsidiaries in December 2025 followed by a gain‑on‑disposal; equity issuance at very low prices; a costly short‑term loan; the acquisition of Acellent HK (shares as consideration) to pivot into AI; and on June 30, 2026, an agreement to sell the Taiwan R&D subsidiary for $490,000. These moves prioritize survival over compounding, dilute existing owners, and effectively abandon the original biomedical investment case.